Lupkynis Approved for Active Lupus Nephritis
The approval was based on data from the pivotal phase 3 AURORA and phase 2 AURA-LV studies.
Lupus Nephritis
Kidney Disease in SLE Possible Despite Low-Level Proteinuria
Based on new findings from a study of patients with systemic lupus erythematosus, investigators suggest revising current guidelines to expand kidney biopsy indications to include isolated proteinuria of any grade.
Rituximab Plus Cyclophosphamide Followed by Belimumab Safe for Refractory Lupus Nephritis Treatment
Researchers evaluated the safety, mechanism of action, and preliminary efficacy of rituximab and cyclophosphamide followed by belimumab in the treatment of refractory lupus nephritis.
Severe Renal Arteriosclerosis in Lupus Nephritis Predicts ASCVD
Severe renal arteriosclerosis in diagnostic lupus nephritis biopsies is associated with 9-fold higher odds of atherosclerotic cardiovascular disease.
Study Finds Clues to Rapid Progression to ESKD in Lupus Nephritis
A small study suggests that poor medication compliance and certain histopathologic features may be associated with development of end-stage kidney disease within 3 years of lupus nephritis diagnosis.
Hydroxychloroquine Level Tied to Thrombosis Risk in Lupus
Rate of thrombotic events lower for patients with mean HCQ blood levels >1,068 versus <648 ng/mL
Belimumab Approved for Active Lupus Nephritis in Adults
In a randomized trial, belimumab (Benlysta) vs placebo added to standard therapy demonstrated superiority in achieving the primary efficacy renal response at 104 weeks.
Mycophenolate Mofetil vs Cyclophosphamide in the Induction Treatment of Lupus Nephritis
Researchers evaluated the efficacy and safety of the induction treatment with mycophenolate mofetil and cyclophosphamide for lupus nephritis.
Low Platelet Distribution Width May Predict Lupus Nephritis
Patients with systematic lupus erythematosus who have a low platelet distribution width (PDW) are more likely to have lupus nephritis than those with a normal or high PDW, a study found.
Voclosporin Granted Priority Review for Lupus Nephritis
The FDA will give Priority Review to the New Drug Application (NDA) of voclosporin (Aurinia Pharmaceuticals) for the treatment of lupus nephritis.
-
Loading...
-
Loading...
Next post in Lupus Nephritis
